EVALUATION OF ACUTE PHASE INFLAMMATION MARKERS IN PATIENTS WITH CHRONIC HEART FAILURE WHO HAVE RECOVERED FROM COVID-19

Rakhmatullaeva G.K., Nazarov N.N., Donabaeva M.H.

dc.contributor.author	Rakhmatullaeva G.K., Nazarov N.N., Donabaeva M.H.
dc.date.accessioned	2024-05-21T06:13:51Z
dc.date.available	2024-05-21T06:13:51Z
dc.date.issued	2024-05-21
dc.identifier.issn	2942-1918
dc.identifier.uri	http://repository.tma.uz/xmlui/handle/1/11061
dc.description.abstract	During the COVID-19 pandemic, the mortality rate from chronic heart failure has significantly increased compared to patients with chronic heart failure who were not infected.In the early stages of the disease, the use of enzyme-linked immunosorbent assays as sensitive methods, in addition to traditional clinical and laboratory methods, is a relevant task for early detection of clinical signs of the disease. (1,2,3) The assessment of endothelial function in patients with chronic heart failure who have recovered from COVID-19 worldwide is important to prevent complications that may arise after the illness. (4,5,6) A key and important aspect of this is the determination of the quantity of endothelial dysfunction biomarkers in the blood of patients with chronic heart failure who have recovered from COVID-19.	en_US
dc.language.iso	en	en_US
dc.relation.ispartofseries	Volume 2 ISSUE 5;
dc.subject	COVID-19, acute phase inflammation markers, chronic heart failure.	en_US
dc.title	EVALUATION OF ACUTE PHASE INFLAMMATION MARKERS IN PATIENTS WITH CHRONIC HEART FAILURE WHO HAVE RECOVERED FROM COVID-19	en_US
dc.title.alternative	Western European Journal of Medicine and Medical Science	en_US
dc.type	Article	en_US